Results 31 to 40 of about 6,405 (201)

Adaptive immunity increases the pace and predictability of evolutionary change in commensal gut bacteria [PDF]

open access: yes, 2015
Co-evolution between the mammalian immune system and the gut microbiota is believed to have shaped the microbiota's astonishing diversity. Here we test the corollary hypothesis that the adaptive immune system, directly or indirectly, influences the ...
Barroso-Batista, João   +2 more
core   +1 more source

Nitrofurans for External Use (Review)

open access: yesРазработка и регистрация лекарственных средств, 2019
Introduction. Aspects of the use of nitrofurans for external use (nitrofural, furazolidone and furazidin) are described in the article. Review of current research that is dedicated to development of drugs containing nitrofuran derivatives has been ...
A. V. Beliatskaya   +5 more
doaj   +1 more source

A Paper-Based Electrochemical Sensor Based on PtNP/COFTFPB−DHzDS@rGO for Sensitive Detection of Furazolidone

open access: yesBiosensors, 2022
Herein, a paper-based electrochemical sensor based on PtNP/COFTFPB−DHzDS@rGO was developed for the sensitive detection of furazolidone. A cluster-like covalent organic framework (COFTFPB−DHzDS) was successfully grown on the surface of amino-functional ...
Rongfang Chen   +3 more
doaj   +1 more source

Optimum Treatment Regimens for Helicobacter Pylori Infection [PDF]

open access: yes, 2000
The treatment of Helicobacter pylori infection includes of current standard triple therapies consisting of a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole on the basis of simplicity, safety, and efficacy.
Hunt, R. H. (Richard)
core   +1 more source

Low Helicobacter pylori eradication rates with 4- and 7-day regimens in an Iranian population [PDF]

open access: yes
Background: In Iran, there is insufficient information on the efficacy of Helicobacter pylori eradication regimens shorter than 10 days. This study aims at assessing the efficacy of 4- and 7-day H. pylori eradication regimens in a high-incidence area of
بابایی, مسعود   +15 more
core   +1 more source

PREVALENCE OF COCCIDIOSIS IN DOGS ALONG WITH HAEMATOLOGICAL ALTERATIONS AS A RESULT OF CHEMOTHERAPEUTIC TRIAL [PDF]

open access: yesPakistan Veterinary Journal, 2009
A case control study was conducted on 200 dogs to ascertain the prevalence of coccidiosis (Isosporiosis). A chemotherapeutic trial was also conducted to compare the efficacy of Co-trimoxazole and Furazolidone along with the effect of Isosporiosis and ...
M. NISAR, J. A. KHAN1, M. S. KHAN1 AND I. A. KHAN
doaj  

Current Diagnosis and Management of Helicobacter Pylori [PDF]

open access: yes, 2013
Helicobacter pylori (H. pylori) is a microbe which cause chronic infection in human. Currently, the prevalence in developed countries continue to decrease, but the same does not happen in developing countries.
Darnindro, N. (Nikko), Syam, A. F. (Ari)
core   +1 more source

Detection of Prohibited Fish Drugs Using Silver Nanowires as Substrate for Surface-Enhanced Raman Scattering

open access: yesNanomaterials, 2016
Surface-enhanced Raman scattering or surface-enhanced Raman spectroscopy (SERS) is a promising detection technology, and has captured increasing attention.
Jia Song   +6 more
doaj   +1 more source

Interference Free HPLC-SERS for the Trace Analysis of Residual Furazolidones in the Aquaculture Sediment

open access: yesChemosensors, 2022
Furazolidone (FZD), a typical highly effective nitrofuran antibiotic, has been banned in aquaculture for its carcinogenicity and other adverse health effects, but it is still wildly used for its low cost and significant efficacy.
Boming Zeng, Yuting Huang, Meikun Fan
doaj   +1 more source

Review article: the global emergence of Helicobacter pylori antibiotic resistance. [PDF]

open access: yes, 2016
BackgroundHelicobacter pylori is one of the most prevalent global pathogens and can lead to gastrointestinal disease including peptic ulcers, gastric marginal zone lymphoma and gastric carcinoma.AimTo review recent trends in H.
Aramin, H   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy